Top Medical News
Rituximab, cyclophosphamide deliver similar effects on ENT symptoms in AAV
Cyclophosphamide (CYC) and rituximab (RTX) show comparable therapeutic effects on ear, nose, and throat (ENT) symptoms in patients with antineutrophil cytoplasmic antibody–associated vasculitis (AAV).
Young adults with SLE at higher risk of 30-day rehospitalization
2 days ago
A Medicare cohort study has found a very high 30-day rehospitalization rate among young adults with systemic lupus erythematosus (SLE).
Serum urate lowering confers protection against fracture in gout
3 days ago
Among people with gout, reducing serum urate levels to the guideline-based target level appears to contribute to a protective effect on the risk of incident fracture, according to a study.
Ageing linked to seronegativity in RA
3 days ago
Ageing is independently associated with seronegative rheumatoid arthritis (RA) in patients who are female, have a nonsmoking history, and a body mass index (BMI) <25 kg/m2, according to a study.
Vitamin E supplements a cure for rheumatoid arthritis?
18 Mar 2023
Supplementation with vitamin E fixes the intestinal barrier and the gastrointestinal tract, which then helps prevent and treat rheumatoid arthritis (RA), reveals a study.
Which factors predict progression from discoid lupus to severe SLE?
14 Mar 2023
A diagnosis of discoid lupus erythematosus (DLE) at age 25 years or below, phototype V to VI, and antinuclear antibody titers of ≥1:320 are significantly associated with the development of severe systemic lupus erythematosus (SLE), according to a study.
Short-term risk of certain cancers similar in RA, PsA patients treated with JAK, TNF inhibitors
12 Mar 2023
For patients with rheumatoid arthritis (RA) or psoriatic arthritis (PsA), initiation of Janus kinase (JAK) inhibitor treatment does not carry a higher short-term risk of cancer, with the exception of nonmelanoma skin cancer (NMSC), as compared with initiation of biological disease-modifying antirheumatic drugs (bDMARDs) including tumour necrosis factor (TNF) inhibitors, according to a study.
Conference Reports
Deucravacitinib bestows benefits in Asian patients with plaque psoriasis
Roshini Claire Anthony, 04 Oct 2022

The benefit of deucravacitinib in moderate to severe plaque psoriasis was demonstrated in a population of Asian patients, according to results of the phase III POETYK PSO-3 trial.

Baricitinib delays, lowers frequency of flares in JIA
Roshini Claire Anthony, 23 Jun 2022

In patients with juvenile idiopathic arthritis (JIA) with insufficient response to conventional synthetic (cs) or biologic (b) disease-modifying antirheumatic drugs (DMARDs), the JAK*1/2 selective inhibitor baricitinib reduced the frequency and delayed time to disease flares, according to a phase III trial presented at EULAR 2022.

Bimekizumab triumphs in bDMARD-naïve psoriatic arthritis patients
Roshini Claire Anthony, 20 Jun 2022

Patients with psoriatic arthritis (PsA) with no prior exposure to biological disease-modifying antirheumatic drugs (bDMARDs) experience improvements in their condition when treated with bimekizumab, according to results of the phase III BE OPTIMAL trial.

Bimekizumab shows promise across the spectrum of axial spondyloarthritis
Elaine Soliven, 18 Jun 2022
Treatment with bimekizumab, a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F and IL-17A, significantly improved ASAS40* response rate in patients with either nonradiographic axial spondyloarthritis (nr-axSpA) or ankylosing spondylitis (AS**), according to two phase III studies presented at EULAR 2022.
Antihistamines potentially beneficial for knee OA
Audrey Abella, 17 Jun 2022
The use of antihistamines was associated with reduced structural progression in knee osteoarthritis (OA), according to a post hoc analysis of two large phase III trials.
JAK inhibition with upadacitinib works well in nr-axSpA
Elvira Manzano, 16 Jun 2022
Treatment with upadacitinib improves disease activity, pain, function, and quality of life (QoL) in patients with non-radiographic axial spondyloarthritis (nr-axSpA) in a study touted as the first to evaluate a Janus kinase (JAK) inhibitor for this condition.
Sarilumab shows potential for relapsing polymyalgia rheumatica
Audrey Abella, 15 Jun 2022
The monoclonal antibody sarilumab demonstrated significant efficacy in individuals with relapsing polymyalgia rheumatica (PMR), findings from the phase III SAPHYR trial have shown.